Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001122 · ClinicalTrials.gov registry record · Phase 2

A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly

A Phase 2 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 2
Development phase
74
Enrollment target
2
Study locations

NCT00001122 is a Phase 2 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 74 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001122, a Phase 2 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 2
Development phase
74 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to see if observed therapy can help HIV-positive patients stick to their anti-HIV medication schedule. Observed therapy means that a nurse will watch patients take their medications to make sure that they take them correctly. It is very important that HIV-positive patients take their anti-HIV medications correctly so they get the best possible benefit from them. Taking the drugs correctly, called "adherence," may keep HIV virus levels in the blood (viral load) low for a longer time. Adherence can also slow the development of drug resistance, and this is especially important in patients with early HIV infection who are just beginning treatment. However, anti-HIV medication schedules are often complicated, and many patients have difficulty remembering to take their drugs at the correct time. This study will look at the effectiveness of a plan to help patients with this problem.

Conditions Studied

HIV Infections

Interventions

  • DRUG Efavirenz
  • DRUG Stavudine
  • DRUG Didanosine
  • DRUG Nelfinavir mesylate

Study Locations (2)

California

  • UCSD - San Diego

Texas

  • Univ of Texas Southwestern Med Ctr - Dallas

Trial Details

FieldValue
Enrollment Target 74 participants
Phase Phase 2

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00001122

The ClinicalTrials.gov registry entry for NCT00001122 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (83% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which Efavirenz is the first listed.

NCT00001122 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.

Frequently Asked Questions

What is clinical trial NCT00001122 about?

NCT00001122 is a clinical study titled "A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly". The purpose of this study is to see if observed therapy can help HIV-positive patients stick to their anti-HIV medication schedule. Observed therapy means that a nurse will watch patients take their medications to make sure that they take them correctly. It is very important that HIV-positive patie...

What is the current status of trial NCT00001122?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants.

What conditions does trial NCT00001122 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00001122?

The interventions under investigation include: Efavirenz (DRUG), Stavudine (DRUG), Didanosine (DRUG), Nelfinavir mesylate (DRUG).

Who is sponsoring clinical trial NCT00001122?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00001122 being conducted?

This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.